Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Asset disposition
CC transcript
Quarterly results
Appointed director
Viracta Therapeutics, Inc. (VIRX) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/14/2023 8-K Quarterly results
Docs: "Viracta Therapeutics, Inc. Selected Balance Sheet Highlights June 30, December 31, 2023 2022 Cash, cash equivalents and short-term investments $ 72,867 $ 91,043 Total assets $ 76,859 $ 95,991 Total liabilities $ 36,077 $ 34,888 Stockholders' equity $ 40,782 $ 61,103 Viracta Therapeutics, Inc. Condensed Consolidated Statement of Operations and Comprehensive Loss Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Operating expenses: Research and development $ 8,197 $ 6,324 $ 15,804 $ 12,420 General and administrative 4,253 4,181 8,853 8,517 Total operating expenses 12,450 10,505 24,657 20,937 Loss from operations Total other expense Net loss Unrealized gain on short-term investments — 63 — Comprehensive loss Net loss per share, basic and diluted $ $ $ $ Weight..."
05/08/2023 8-K Quarterly results
Docs: "-- Financial tables attached – Viracta Therapeutics, Inc. Selected Balance Sheet Highlights March 31, December 31, 2023 2022 Cash, cash equivalents and short-term investments $ 80,332 $ 91,043 Total assets $ 85,781 $ 95,991 Total liabilities $ 34,668 $ 34,888 Stockholders' equity $ 51,113 $ 61,103 Viracta Therapeutics, Inc. Condensed Consolidated Statement of Operations and Comprehensive Loss Three Months Ended March 31, 2023 2022 Operating expenses: Research and development $ 7,607 $ 6,096 General and administrative 4,600 4,336 Total operating expenses 12,207 10,432 Loss from operations Total other expense Net loss Unrealized gain on short-term investments 91 — Comprehensive loss Net loss per share, basic and diluted $ $ Weighted-average common shares outstanding, basic and diluted 3..."
03/13/2023 8-K Quarterly results
Docs: "Viracta Therapeutics, Inc. Selected Balance Sheet Highlights December 31, 2022 2021 Cash, cash equivalents and short-term investments $ 91,043 $ 103,554 Total assets $ 95,991 $ 108,552 Total liabilities $ 34,888 $ 14,181stockholders' equity $ 61,103 $ 94,371 Viracta Therapeutics, Inc. Condensed Consolidated Statement of Operations and Comprehensive Loss Three Months Ended December 31, Year Ended December 31, 2022 2021 2022 2021 Operating expenses: Research and development $ 6,703 $ 7,303 $ 26,262 $ 23,861 Purchased and acquired in-process research and development — — — 88,478 General and administrative 4,871 4,015 24,327 15,437 Total operating expenses 11,574 11,318 50,589 127,776 Gain on Royalty Purchase Agreement — — — 13,500 Loss from operations Total other income 1,248 1,392 Net loss..."
11/10/2022 8-K Quarterly results
08/09/2022 8-K Quarterly results
05/10/2022 8-K Quarterly results
03/16/2022 8-K Quarterly results
Docs: "Viracta Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Corporate Update Final Phase 1b/2 data showing promising and durable signal of efficacy for Nana-val in patients with relapsed/refractory Epstein-Barr virus-positive lymphoma featured in an oral presentation at ASH 2021 Pivotal NAVAL-1 trial of Nana-val for the treatment of EBV+ lymphoma is enrolling patients and an update on the initial cohort expanding into Stage 2 is anticipated in the second half of 2022 Preliminary safety and efficacy data from the Phase 1b/2 trial of Nana-val for the treatment of advanced EBV+ solid tumors is expected in the second half of 2022 Cash balance of $103.6 million as of December 31, 2021, expected to be sufficient to fund operations into mid-2024"
11/10/2021 8-K Quarterly results
Docs: "Viracta Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update Announced that final results of Phase 1b/2 trial of nanatinostat and valganciclovir in relapsed/refractory Epstein-Barr virus-positive lymphoma were selected for an oral presentation at the 2021 American Society of Hematology Annual Meeting Continued the global expansion of pivotal NAVAL-1 trial of Nana-val in R/R EBV+ lymphoma; multiple U.S. and international sites now open for enrollment Initiated Phase 1b/2 trial of Nana-val in patients with EBV+ solid tumors; preliminary data anticipated in 2022 Announced that preclinical data on vecabrutinib was selected for oral and poster presentations at ASH Secured expanded $50 million credit facility from Silicon Valley Bank and Oxford Finance Cash and..."
08/12/2021 8-K Quarterly results
Docs: "Viracta Therapeutics Reports Second Quarter 2021 Financial Results and Provides Clinical and Corporate Updates",
"Corporate Presentation of Viracta Therapeutics, Inc"
05/12/2021 8-K Quarterly results
11/16/2020 8-K Quarterly results
Docs: "Sunesis Pharmaceuticals Reports Third Quarter 2020 Financial Results and Recent Highlights Sunesis to Host Conference Call Today at 4:30 PM Eastern Time"
08/11/2020 8-K Quarterly results
05/07/2020 8-K Quarterly results
03/10/2020 8-K Quarterly results
11/12/2019 8-K Quarterly results
08/07/2019 8-K Quarterly results
Docs: "Sunesis Pharmaceuticals Reports Second Quarter 2019 Financial Results and Recent Highlights Sunesis to Host Conference Call Today at 4:30 PM Eastern Time"
05/08/2019 8-K Quarterly results
Docs: "Sunesis Pharmaceuticals Reports First Quarter 2019 Financial Results and Recent Highlights Phase 1b/2 Trial of Vecabrutinib Advances into 200 mg Cohort Sunesis to Host Conference Call Today at 4:30 PM Eastern Time"
03/07/2019 8-K Quarterly results
03/08/2018 8-K Quarterly results
Docs: "Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2017 Financial Results and Recent Highlights Sunesis to Host Conference Call Today at 4:30 PM Eastern Time"
11/02/2017 8-K Quarterly results
Docs: "FORM 8-K",
"Sunesis Pharmaceuticals Reports Third Quarter 2017 Financial Results and Recent Highlights"
07/27/2017 8-K Form 8-K - Current report:
05/08/2017 8-K Form 8-K - Current report
03/09/2017 8-K Form 8-K - Current report
11/03/2016 8-K Form 8-K - Current report
07/29/2016 8-K Form 8-K - Current report
05/11/2016 8-K Form 8-K - Current report
03/10/2016 8-K Form 8-K - Current report
11/05/2015 8-K Quarterly results
Docs: "Sunesis Pharmaceuticals Reports Third Quarter 2015 Financial Results and Recent Highlights"
07/30/2015 8-K Quarterly results
Docs: "Sunesis Pharmaceuticals Reports Second Quarter 2015 Financial Results and Recent Highlights"
05/05/2015 8-K Quarterly results
Docs: "Sunesis Pharmaceuticals Reports First Quarter 2015 Financial Results and Recent Highlights"
03/12/2015 8-K Quarterly results
Docs: "Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2014 Financial Results and Recent Highlights"
11/10/2014 8-K Quarterly results
Docs: "Sunesis Pharmaceuticals Reports Third Quarter 2014 Financial Results and Recent Highlights"
08/05/2014 8-K Quarterly results
Docs: "Sunesis Pharmaceuticals Reports Second Quarter 2014 Financial Results and Recent Highlights"
05/07/2014 8-K Quarterly results
Docs: "Sunesis Pharmaceuticals Reports First Quarter 2014 Financial Results and Recent Highlights",
"Sunesis Pharmaceuticals Reports First Quarter 2014 Financial Results and Recent Highlights"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy